GAAD评分在非肝硬化局灶性肝病变中的临床效用与诊断准确性
多中心前瞻性研究纳入583例非肝硬化局灶性肝病变患者,其中73例(12.5%)为肝细胞癌。GAAD评分在预设切点≥2.57时灵敏度85%、特异度96%、阳性预测值75%、阴性预测值98%,鉴别效能优于单独AFP和PIVKA-II,且不受基础慢性肝病影响。
要点
- GAAD评分在非肝硬化局灶性肝病变中高预测肝细胞癌,鉴别效能优于单独AFP和PIVKA-II。
- 预设切点≥2.57时灵敏度85%、特异度96%、阳性预测值75%、阴性预测值98%。
- GAAD评分表现不受基础慢性肝病、病毒性肝炎或脂肪性肝病存在与否影响。
核心结论
- 在非肝硬化局灶性肝病变患者中,GAAD评分对肝细胞癌高度预测,诊断准确性优于单独AFP和PIVKA-II。
研究设计与样本
- 多中心前瞻性研究,连续纳入荷兰2家三级转诊诊所的非肝硬化局灶性肝病变患者,共583例,其中73例(12.5%)为肝细胞癌。
主要发现
- GAAD评分鉴别肝细胞癌的AUC为0.96,优于AFP的0.75(P < .01)和PIVKA-II的0.91(P = .01)。
- GAAD切点≥2.57时灵敏度85%、特异度96%、阳性预测值75%、阴性预测值98%,特异度优于PIVKA-II,灵敏度优于AFP。
- GAAD表现不受基础慢性肝病影响(AUC 0.93 vs 0.97;P = .23),不受病毒性肝炎影响(AUC 0.99 vs 0.96;P = .05),不受脂肪性肝病影响(AUC 0.92 vs 0.98;P = .19)。
关键数值与推荐
- GAAD评分基于患者年龄、性别及血清甲胎蛋白(AFP)和维生素K缺乏诱导蛋白-II(PIVKA-II)水平,预设切点为≥2.57。
临床怎么用
- GAAD评分可用于指导非肝硬化局灶性肝病变患者的管理决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Focal liver lesions are frequently encountered, often as incidentalomas, in patients without cirrhosis. There is an urgent unmet need for noninvasive tests to distinguish hepatocellular carcinoma (HCC) from other lesions. We studied the diagnostic accuracy of the GAAD score, which is based on patient age, sex and serum values of α-fetoprotein (AFP) and protein induced by vitamin K absence-II (PIVKA-II; also known as Des-γ-carboxyprothrombin), in non-cirrhotic patients with focal liver lesions. METHODS: In a multi-center prospective study, all consecutive patients presenting with focal liver lesions in a non-cirrhotic liver were enrolled from 2 tertiary referral clinics in the Netherlands. The diagnostic accuracy of the GAAD score was assessed at its predefined cutoff of ≥2.57 and compared with AFP and PIVKA-II alone in the overall study population and after stratification by lesion size and presence of underlying liver disease. RESULTS: A total of 583 patients were included, of whom 73 (12.5%) had HCC. The GAAD score offered superior discrimination over AFP (area under the receiver operating characteristic curve [AUC] 0.96 vs 0.75; P < .01) and PIVKA-II (AUC 0.96 vs 0.91; P = .01). At a GAAD cutoff of ≥2.57, the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were 85%, 96%, 75%, and 98%, with GAAD offering superior specificity over PIVKA-II and superior sensitivity over AFP. The performance of GAAD was consistent regardless of the presence of an underlying chronic liver disease (AUC 0.93 vs 0.97; P = .23), and regardless of the presence of viral hepatitis (AUC 0.99 vs 0.96; P = .05) or steatotic liver disease (AUC 0.92 vs 0.98; P = .19). CONCLUSIONS: In this cohort of non-cirrhotic patients with focal liver lesions, the GAAD score was highly predictive of HCC and offered superior diagnostic accuracy over AFP and PIVKA-II alone. These findings support the use of the GAAD score to guide management decisions in these patients.
引用
- Moussa M, Sprengers D, Ketting V, et al. Clinical Utility and Diagnostic Accuracy of the GAAD Score in Non-Cirrhotic Patients With Focal Liver Lesions. Clin Gastroenterol Hepatol. 2026. PMID: 41672262. doi:10.1016/j.cgh.2026.01.042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。